Verastem Oncology has announced the discontinuation of its RAMP 203 Phase 1/2 trial evaluating avutometinib and defactinib in combination with Amgen’s KRAS G12C inhibitor sotorasib in advanced KRAS G12C-mutant non-small cell lung cancer. The move comes as the company redirects resources toward the clinical development of its in-house KRAS G12D inhibitor, VS-7375, which has shown encouraging early signals in multiple solid tumors including lung cancer

This development underscores a broader transition within the KRAS-targeted therapy space, where G12C-focused approaches are beginning to show limitations amid rising clinical expectations. The realignment reflects not only the competitive dynamics in the G12C category but also Verastem Oncology’s strategic shift toward areas where it can lead rather than follow.

What Verastem Oncology’s trial exit tells us about the evolution of KRAS G12C therapies

Verastem Oncology’s decision to shut down RAMP 203 appears to be less about clinical failure and more about forward-looking prioritization. While the avutometinib–defactinib–sotorasib combination demonstrated biological activity and manageable safety, next-generation G12C inhibitors are now resetting benchmarks with stronger response rates and more durable efficacy.

The company cited these evolving standards as a rationale for ceasing further enrollment in RAMP 203, despite some favorable results in treatment-naïve patients. It reflects a sober reading of the market: a moderately effective add-on strategy is unlikely to be commercially viable when superior monotherapies are emerging. In essence, Verastem Oncology is exiting a crowded field to pursue a target where it believes it can lead clinical innovation, not merely contribute incremental benefit.

This development mirrors a broader trend in oncology, where the half-life of competitive advantage in mutation-targeted therapies is increasingly short. The KRAS G12C space has rapidly matured from first-in-class approvals to second-generation challengers, some of which are pursuing irreversible covalent binding, mutant-selective degradation, or immune modulation. In this environment, standing still is the same as falling behind.

Why Verastem is pivoting to KRAS G12D: a more addressable mutation with broader relevance

At the center of Verastem Oncology’s new focus is VS-7375, a KRAS G12D inhibitor using an ON/OFF modulation mechanism. The compound has shown a 69 percent response rate in a 16-patient cohort with advanced KRAS G12D-mutant non-small cell lung cancer. Though the responses include unconfirmed data and the sample size is small, the figure is well above the typical response rates seen in G12C-targeted trials.

The KRAS G12D mutation is also more prevalent than G12C across several solid tumor types, including pancreatic, colorectal, and lung cancers. This prevalence opens up a wider commercial and clinical playing field. While KRAS G12C is found in approximately 13 percent of NSCLC cases, KRAS G12D mutations account for a larger share of colorectal and pancreatic cancers, two areas where unmet need remains especially high.

Verastem Oncology’s compound targets this mutation with a unique ON/OFF approach, believed to dynamically modulate KRAS activity instead of locking it in one state. This may improve its capacity to avoid or delay resistance mechanisms. While this hypothesis still requires validation in later-stage trials, it gives Verastem a differentiated scientific narrative as it moves deeper into KRAS G12D development.

What RAMP 203 data revealed about G12C-targeted combination approaches

Despite the trial’s discontinuation, RAMP 203 produced a useful dataset across multiple patient subsets. Among 30 KRAS G12C-inhibitor-naïve patients receiving the avutometinib and sotorasib doublet, the overall response rate reached 40 percent, with a median progression-free survival of 11.1 months. However, for 21 patients previously treated with a G12C inhibitor, the response rate dropped sharply to 9.5 percent with a PFS of just 3.7 months.

In the triplet cohort involving avutometinib, defactinib, and sotorasib, only four patients in the G12C-inhibitor-naïve group were evaluable. Two responded, while one achieved stable disease. Among 12 previously treated patients in the triplet arm, 11 were evaluable and 36 percent achieved significant tumor reduction. Median progression-free survival in this subset was 3.6 months.

From a safety standpoint, the combinations appeared tolerable. No dose-limiting toxicities were observed, and adverse events like nausea, diarrhea, and fatigue were the most common. While these data do not suggest a safety barrier, they reinforce the impression that efficacy, not tolerability, is the limiting factor for this combination in an increasingly competitive G12C landscape

How this aligns with Verastem’s broader strategy around avutometinib and defactinib

Verastem Oncology is not shelving avutometinib or defactinib entirely. The two compounds are already approved under the co-packaged label AVMAPKI FAKZYNJA for the treatment of recurrent low-grade serous ovarian cancer with KRAS mutations. Accelerated approval was granted by the U.S. Food and Drug Administration in May 2025, with continued approval contingent on confirmatory data from the ongoing RAMP 301 trial.

In that context, RAMP 203’s results serve more as boundary conditions than as failure. The trial appears to have confirmed the biological rationale for the MEK–FAK dual inhibition approach, but highlighted its limits in pretreated KRAS G12C-mutant NSCLC. Verastem is now redirecting that strategy into other areas with potentially greater traction, including metastatic pancreatic cancer, where the RAMP 205 trial is evaluating the combination alongside chemotherapy in the first-line setting.

This repositioning demonstrates a pragmatic pipeline architecture. Rather than abandoning its approved therapies, Verastem Oncology is rerouting them into domains where standard-of-care regimens may benefit more from mechanistic synergy and where the competitive field is less congested.

What remains uncertain about VS-7375’s future trajectory

While Verastem Oncology’s pivot to VS-7375 makes strategic sense, it carries notable clinical and regulatory risks. The early response rate of 69 percent, although encouraging, is drawn from a small cohort and includes unconfirmed responses. Whether this efficacy signal holds up in larger, more diverse populations remains a major question.

The durability of response is also unclear. ON/OFF modulation of KRAS may avoid resistance better than irreversible inhibitors, but it could also introduce new dosing or tolerability challenges. Long-term data will be critical in evaluating whether this approach truly represents a generational leap or simply another iteration in a crowded pipeline.

Regulatory pathing is another unresolved variable. Verastem Oncology must now decide whether to pursue accelerated approval in specific indications or run broader randomized studies that support first-line use. The former could enable faster commercialization but carries post-approval risk, while the latter requires more capital and clinical time.

The broader G12D competitive field is also heating up. Other biotechnology companies, including Mirati Therapeutics and Revolution Medicines, are pursuing G12D-targeted compounds, and academic groups are exploring novel KRAS-binding scaffolds. Verastem will need to differentiate both on science and speed if it hopes to maintain lead position.

Why this pivot matters for the future of RAS-targeted therapies

The decision to discontinue RAMP 203 is emblematic of how quickly the field of targeted oncology is evolving. Success in earlier programs no longer guarantees a seat at the table as newer entrants redefine what constitutes clinical relevance. Verastem Oncology’s realignment shows a willingness to walk away from projects that may no longer be viable and reinvest where opportunity is larger and less saturated.

If successful, the VS-7375 program could redefine the standard of care for KRAS G12D-mutant cancers, which currently lack highly effective targeted options. And even if it falls short, the pivot demonstrates a blueprint for small to mid-sized biopharmaceutical companies navigating rapidly shifting innovation thresholds in targeted therapy.

  Amgen, avutometinib, biotech pipeline, defactinib, KRAS G12D, MAPK, non-small cell lung cancer, oncology, RAMP 203, sotorasib, targeted therapy, Verastem Oncology, VS-7375